View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 11, 2020

Keystone Heart secures CE Mark for cerebral embolic protection device

Venus Medtech Company Keystone Heart has secured CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) devicem which minimises the risk of cerebral complications during transcatheter heart procedures.

Venus Medtech Company Keystone Heart has secured CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) device, which minimises the risk of cerebral complications during transcatheter heart procedures.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Cerebrovascular complications are considered the most feared threats in the Transcatheter Aortic Valve Implantation (TAVI) and other transcatheter heart procedures.

TriGUARD 3 CEP device deflects embolic debris away from cerebral circulation to reduce the chances of cerebral damage during such procedures.

It is the only CE Marked device created to cover and protect all three major cerebral aortic arch vessels.

Furthermore, the device features Nitinol frame and dome-shaped mesh deflector, delivered transfemorally and devised to ‘self-position’ in the aortic arch.

This design enables the device to adapt to different patient anatomies.

Keystone Heart president and CEO Chris Richardson said: “Taking into consideration the devastating impact of stroke, we are pleased to bring this important technology to patients undergoing any transcatheter heart procedure.

“The introduction of the TriGUARD 3 CEP Device in Europe provides physicians with the only commercially available device that is designed to protect all three cerebral vessels.”

In June 2018, the company initiated a pivotal randomised Phase II clinical trial (REFLECT) of its TriGUARD 3 CEP device, intended to assess the safety and efficacy of the device in around 275 patients. It was recently completed by Keystone Heart.

Currently, the company is finalising data analysis to approach the US Food and Drug Administration (FDA) with the marketing application.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network